Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2

References

• 1 Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 21(2), 140–146 (2009).
  Medline CASGoogle Scholar
• 2 Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9(1), 28–39 (2009).
  MedlineGoogle Scholar
• 3 Levitzki A. Tyrosine kinase inhibitors views of selectivity, sensitivity, and clinical performance. Ann. Rev. Pharmacol. Toxicol. 53, 161–185 (2013).
  Medline CASGoogle Scholar
• 4 Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ. Mechanisms of drug combinations interaction and network perspectives. Nat. Rev. Drug Discov. 8(2), 111–128 (2009).
  Medline CASGoogle Scholar
• 5 Hanahan D. Rethinking the war on cancer. Lancet 383(9916), 558–563 (2013).
  MedlineGoogle Scholar
• 6 Hopkins AL. Network pharmacology the next paradigm in drug discovery. Nat. Chem. Bio. 4(11), 682–690 (2008).
  Medline CASGoogle Scholar
• 7 Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733–2743 (2006).
  Medline CASGoogle Scholar
• 8 Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30(7), 679–692 (2012).
  Medline CASGoogle Scholar
• 9 Costantino L, Barlocco D. Challenges in the design of multitarget drugs against multifactorial pathologies a new life for medicinal chemistry? Future Med. Chem. 5(1), 5–7 (2013).
  CASGoogle Scholar
• 10 Peters JU. Polypharmacology – foe or friend? J. Med. Chem. 56(22), 8955–8971 (2013).
  Medline CASGoogle Scholar
• 11 Rosini M. Polypharmacology the rise of multitarget drugs over combination therapies. Future Med. Chem. 6(5), 485–487 (2014).
  CASGoogle Scholar
• 12 Musumeci F, Radi M, Brullo C, Schenone S. Vascular endothelial growth factor (VEGF) receptors drugs and new inhibitors. J. Med. Chem. 55(24), 10797–10822 (2012).
  Medline CASGoogle Scholar
• 13 Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8(8), 579–591 (2008).
  Medline CASGoogle Scholar
• 14 Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl Acad. Sci. USA 94(14), 7192–7197 (1997).
  Medline CASGoogle Scholar
• 15 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18(1), 4–25 (1997).
  Medline CASGoogle Scholar
• 16 Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct. 26(1), 25–35 (2001).
  Medline CASGoogle Scholar
• 17 Stuttfeld E, Ballmer‐Hofer K. Structure and function of VEGF receptors. IUBMB Life 61(9), 915–922 (2009).
  Medline CASGoogle Scholar
• 18 Wang JF, Zhang X, Groopman JE. Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress. J. Biol. Chem. 279(26), 27088–27097 (2004).
  Medline CASGoogle Scholar
• 19 Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 12(17), 5018–5022 (2006).
  Medline CASGoogle Scholar
• 20 Dayanir V, Meyer RD, Lashkari K, Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J. Biol. Chem. 276(21), 17686–17692 (2001).
  Medline CASGoogle Scholar
• 21 Lamalice L, Houle F, Jourdan G, Huot J. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 23(2), 434–445 (2004).
  Medline CASGoogle Scholar
• 22 Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15(18), 2169–2177 (1997).
  Medline CASGoogle Scholar
• 23 Zhang C, Tan C, Ding H, Xin T, Jiang Y. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials. Curr. Pharm. Des. 18(20), 2921–2935 (2012).
  Medline CASGoogle Scholar
• 24 Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1–independent and HIF-1–dependent mechanisms. Cancer Res. 66(6), 3197–3204 (2006).
  Medline CASGoogle Scholar
• 25 Sini P, Wyder L, Schnell C et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin. Cancer Res. 11(12), 4521–4532 (2005).
  Medline CASGoogle Scholar
• 26 Naumov GN, Nilsson MB, Cascone T et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 15(10), 3484–3494 (2009).
  Medline CASGoogle Scholar
• 27 Poindessous V, Ouaret D, El Ouadrani K et al. EGFR-and VEGF (R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin. Cancer Res. 17(20), 6522–6530 (2011).
  Medline CASGoogle Scholar
• 28 Wells SA, Gosnell JE, Gagel RF et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 28(5), 767–772 (2010).
  Medline CASGoogle Scholar
• 29 Wells SA, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer a randomized, double-blind Phase III trial. J. Clin. Oncol. 30(2), 134–141 (2012).
  Medline CASGoogle Scholar
• 30 Rodríguez-Antona C, Pallares J, Montero-Conde C et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr. Relat. Cancer 17(1), 7–16 (2010).
  Medline CASGoogle Scholar
• 31 Herbst RS, Sun Y, Eberhardt WE et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC) a double-blind, randomised, Phase 3 trial. Lancet Oncol. 11(7), 619–626 (2010).
  Medline CASGoogle Scholar
• 32 Reardon DA, Conrad CA, Cloughesy T et al. Phase I study of AEE788, a novel multitarget inhibitor of ErbB-and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother. Pharmacol. 69(6), 1507–1518 (2012).
  Medline CASGoogle Scholar
• 33 Baselga J, Mita AC, Schöffski P et al. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development a Phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. Clin. Cancer Res. 18(22), 6364–6372 (2012).
  Medline CASGoogle Scholar
• 34 Soria JC, Baselga J, Hanna N et al. Phase I–IIa study of BMS-690514, an EGFR, HER-2 and-4 and VEGFR-1 to-3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur. J. Cancer 49(8), 1815–1824 (2013).
  Medline CASGoogle Scholar
• 35 Chow LQ, Jonker DI, Dy GK et al. A Phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies. Cancer Chemother. Pharmacol. 71(5), 1273–1285 (2013).
  Medline CASGoogle Scholar
• 36 Gherardi E, Birchmeier W, Birchmeier C, Woude GV. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12(2), 89–103 (2012).
  Medline CASGoogle Scholar
• 37 Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 19(10), 542–551 (2009).
  Medline CASGoogle Scholar
• 38 Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10(11), 760–774 (2010).
  Medline CASGoogle Scholar
• 39 Puri N, Khramtsov A, Ahmed S et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67(8), 3529–3534 (2007).
  Medline CASGoogle Scholar
• 40 Sulpice E, Ding S, Muscatelli‐Groux B et al. Cross‐talk between the VEGF‐A and HGF signalling pathways in endothelial cells. Biol. Cell 101(9), 525–539 (2009).
  Medline CASGoogle Scholar
• 41 Cui JJ. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J. Med. Chem. 57(11), 4427–4453 (2013).
  MedlineGoogle Scholar
• 42 Elisei R, Schlumberger MJ, Müller SP et al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31(29), 3639–3646 (2013).
  Medline CASGoogle Scholar
• 43 Kurzrock R, Sherman SI, Ball DW et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29(19), 2660–2666 (2011).
  Medline CASGoogle Scholar
• 44 Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer results of a Phase II randomized discontinuation trial. J. Clin. Oncol. 31(4), 412–419 (2013).
  Medline CASGoogle Scholar
• 45 Choueiri TK, Vaishampayan U, Rosenberg JE et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol. 31(2), 181–186 (2013).
  Medline CASGoogle Scholar
• 46 Shah MA, Wainberg ZA, Catenacci DV et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE 8(3), e54014 (2013).
  Medline CASGoogle Scholar
• 47 Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G Jr. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest. New Drugs 31(2), 417–424 (2013).
  Medline CASGoogle Scholar
• 48 Shapiro GI, Mccallum S, Adams LM et al. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest. New Drugs 31(3), 742–750 (2013).
  Medline CASGoogle Scholar
• 49 Wang W, Li Q, Takeuchi S et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor–induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin. Cancer Res. 18(6), 1663–1671 (2012).
  Medline CASGoogle Scholar
• 50 Takeuchi S, Wang W, Li Q et al. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am. J. Pathol 181(3), 1034–1043 (2012).
  Medline CASGoogle Scholar
• 51 Nakagawa T, Takeuchi S, Yamada T et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol. Cancer Ther. 11(10), 2149–2157 (2012).
  Medline CASGoogle Scholar
• 52 Besterman JM, Fournel M, Dupont I, Bonfils C, Dubay M, Ste-Croix H. Potent preclinical anti-tumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in Phase II clinical development, in combination with taxanes or erlotinib. J. Clin. Oncol. 28(Suppl.), e13595 (2010). Abstract
  Google Scholar
• 53 Liang G, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol. Sci. 33(10), 531–541 (2012).
  Medline CASGoogle Scholar
• 54 Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22(4), 201–207 (2001).
  Medline CASGoogle Scholar
• 55 Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res. 17(19), 6130–6139 (2011).
  Medline CASGoogle Scholar
• 56 Roth GJ, Heckel A, Colbatzky F et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem. 52(14), 4466–4480 (2009).
  Medline CASGoogle Scholar
• 57 Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1) a Phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15(2), 143–145 (2014).
  Medline CASGoogle Scholar
• 58 Rolfo C, Raez LE, Bronte G et al. BIBF 1120/nintedanib a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin. Investig. Drugs 22(8), 1081–1088 (2013).
  Medline CASGoogle Scholar
• 59 Rashdan S, Hanna N. Nintedanib for the treatment of non-small-cell lung cancer. Expert. Opin. Pharmacother. 15(5), 729–739 (2014).
  Medline CASGoogle Scholar
• 60 Majem M, Pallarès C. An update on molecularly targeted therapies in second-and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. Clin. Transl. Oncol. 15(5), 343–357 (2013).
  Medline CASGoogle Scholar
• 61 Ball DW, Sherman SI, Jarzab B et al. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC) cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. J. Clin. Oncol. 30(15), 5518 (2012).
  Google Scholar
• 62 Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid 23(4), 392–407 (2013).
  Medline CASGoogle Scholar
• 63 Okamoto K, Kodama K, Takase K et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 340(1), 97–103 (2013).
  Medline CASGoogle Scholar
• 64 Johnson PJ, Qin S, Park J-W et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma. Results from the randomized Phase III BRISK-FL study. J. Clin. Oncol. 31(28), 3517–3524 (2013).
  Medline CASGoogle Scholar
• 65 Llovet JM, Decaens T, Raoul JL et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed results from the randomized Phase III BRISK-PS Study. J. Clin. Oncol. 31(28), 3509–3516 (2013).
  Medline CASGoogle Scholar
• 66 Sivanand S, Peña-Llopis S, Zhao H et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci. Transl. Med. 4(137), 137–175 (2012).
  Google Scholar
• 67 Motzer RJ, Porta C, Vogelzang NJ et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma an open-label, randomised Phase 3 trial. Lancet Oncol. 15(3), 286–296 (2014).
  Medline CASGoogle Scholar
• 68 Batchelor TT, Mulholland P, Neyns B et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J. Clin. Oncol. 31(26), 3212–3218 (2013).
  Medline CASGoogle Scholar
• 69 Hoff PM, Hochhaus A, Pestalozzi BC et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer a randomized, double-blind, Phase III study (HORIZON II). J. Clin. Oncol. 30(29), 3596–3603 (2012).
  Medline CASGoogle Scholar
• 70 Schmoll HJ, Cunningham D, Sobrero A et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer a double-blind, randomized Phase III study (HORIZON III). J. Clin. Oncol. 30(29), 3588–3595 (2012).
  Medline CASGoogle Scholar
• 71 Kummar S, Allen D, Monks A et al. Cediranib for metastatic alveolar soft part sarcoma. J. Clin. Oncol. 31(18), 2296–2302 (2013).
  Medline CASGoogle Scholar
• 72 Bello E, Colella G, Scarlato V et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 71(4), 1396–1405 (2011).
  Medline CASGoogle Scholar
• 73 Bello E, Taraboletti G, Colella G et al. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol. Cancer Ther. 12(2), 131–140 (2013).
  Medline CASGoogle Scholar
• 74 Hellstrom M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126(14), 3047–3055 (1999).
  Medline CASGoogle Scholar
• 75 Edling CE, Hallberg B. c-Kit – a hematopoietic cell essential receptor tyrosine kinase. Int. J. Biochem. Cell Biol. 39(11), 1995–1998 (2007).
  Medline CASGoogle Scholar
• 76 Christensen J. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann. Oncol. 18(Suppl. 10), X3–X10 (2007).
  MedlineGoogle Scholar
• 77 Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 46(3), 283–291 (2004).
  MedlineGoogle Scholar
• 78 Potapova O, Laird AD, Nannini MA et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol. Cancer Ther. 5(5), 1280–1289 (2006).
  Medline CASGoogle Scholar
• 79 Motzer R, Hutson T, Tomczak P et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 24(Suppl. 18), S2 (2006).
  Google Scholar
• 80 Casali P, Garrett C, Blackstein M et al. Updated results from a Phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J. Clin. Oncol. 24(Suppl. 18), 9513 (2006).
  Google Scholar
• 81 Demetri GD, Van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib a randomised controlled trial. Lancet 368(9544), 1329–1338 (2006).
  Medline CASGoogle Scholar
• 82 Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 501–513 (2011).
  Medline CASGoogle Scholar
• 83 Deeks ED, Raymond E. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors. BioDrugs 25(5), 307–316 (2011).
  Medline CASGoogle Scholar
• 84 Blumenthal GM, Cortazar P, Zhang JJ et al. FDA approval summary sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist 17(8), 1108–1113 (2012).
  Medline CASGoogle Scholar
• 85 Hutson TE, Lesovoy V, Al-Shukri S et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma a randomised open-label Phase 3 trial. Lancet Oncol. 14(13), 1287–1294 (2013).
  Medline CASGoogle Scholar
• 86 Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma overall survival analysis and updated results from a randomised Phase 3 trial. Lancet Oncol. 14(6), 552–562 (2013).
  Medline CASGoogle Scholar
• 87 Cella D, Escudier B, Rini B et al. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma Phase III (AXIS) trial. Br. J. Cancer 108(8), 1571–1578 (2013).
  Medline CASGoogle Scholar
• 88 I Rini B, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) a randomised Phase 3 trial. Lancet 378(9807), 1931–1939 (2011).
  MedlineGoogle Scholar
• 89 Motzer RJ, Nosov D, Eisen T et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma. Results from a Phase III trial. J. Clin. Oncol. 31(30), 3791–3799 (2013).
  Medline CASGoogle Scholar
• 90 Nosov DA, Esteves B, Lipatov ON et al. Antitumor activity and safety of tivozanib (AV-951) in a Phase II randomized discontinuation trial in patients with renal cell carcinoma. J. Clin. Oncol. 30(14), 1678–1685 (2012).
  Medline CASGoogle Scholar
• 91 Wolpin BM, Ng K, Zhu AX et al. Multicenter Phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist 18(4), 377–378 (2013).
  Medline CASGoogle Scholar
• 92 Toh HC, Chen PJ, Carr BI et al. Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 119(2), 380–387 (2013).
  Medline CASGoogle Scholar
• 93 Toh H, Chen P, Carr B et al. Linifanib Phase II trial in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 28(15S), 4038 (2010).
  MedlineGoogle Scholar
• 94 Chiu Y-L, Carlson DM, Pradhan RS, Ricker JL. Exposure–response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma. Clin. Ther. 35(11), 1770–1777 (2013).
  Medline CASGoogle Scholar
• 95 Strumberg D, Schultheis B, Adamietz I et al. Phase I dose escalation study of telatinib (BAY 57–9352) in patients with advanced solid tumours. Br. J. Cancer 99(10), 1579–1585 (2008).
  Medline CASGoogle Scholar
• 96 Eskens FA, Steeghs N, Verweij J et al. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor β, and c-Kit, in patients with advanced or metastatic solid tumors. J. Clin. Oncol. 27(25), 4169–4176 (2009).
  Medline CASGoogle Scholar
• 97 Ko A, Tabernero J, De Paredes MG et al. Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction (GEJ). J. Clin. Oncol. 28(Suppl.), E1455 (2010). Abstract
  Google Scholar
• 98 Scagliotti GV, Vynnychenko I, Park K et al. International, randomized, placebo-controlled, double-blind Phase III study of Motesanib plus Carboplatin/Paclitaxel in patients with advanced nonsquamous non–small-cell lung cancer MONET1. J. Clin. Oncol. 30(23), 2829–2836 (2012).
  Medline CASGoogle Scholar
• 99 Martin M, Roche H, Pinter T et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer a Phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 12(4), 369–376 (2011).
  Medline CASGoogle Scholar
• 100 Miyamoto N, Sakai N, Hirayama T et al. Discovery of N-[5-({2-[(cyclopropylcarbonyl) amino] imidazo [1, 2-b] pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor. Bioorg. Med. Chem. 21(8), 2333–2345 (2013).
  Medline CASGoogle Scholar
• 101 Awazu Y, Mizutani A, Nagase Y et al. Anti‐angiogenic and anti‐tumor effects of TAK‐593, a potent and selective inhibitor of vascular endothelial growth factor and platelet‐derived growth factor receptor tyrosine kinase. Cancer Sci. 104(4), 486–494 (2013).
  Medline CASGoogle Scholar
• 102 Roberts P, Der C. Targeting the Raf–MEK–ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22), 3291–3310 (2007).
  Medline CASGoogle Scholar
• 103 Bollag G, Tsai J, Zhang J et al. Vemurafenib the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 11(11), 873–886 (2012).
  Medline CASGoogle Scholar
• 104 Piscazzi A, Costantino E, Maddalena F et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 97(6), E898–E906 (2012).
  Medline CASGoogle Scholar
• 105 Fecteau J-F, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol. Med. 18(1), 19 (2012).
  Medline CASGoogle Scholar
• 106 Lang SA, Schachtschneider P, Moser C et al. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol. Cancer Ther. 7(11), 3509–3518 (2008).
  Medline CASGoogle Scholar
• 107 Escudier B, Szczylik C, Eisen T et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 23(Suppl. 16), S380 (2005).
  Google Scholar
• 108 Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125–134 (2007).
  Medline CASGoogle Scholar
• 109 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
  Medline CASGoogle Scholar
• 110 Bruix J, Raoul J-L, Sherman M et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma subanalyses of a Phase III trial. J. Hepatol. 57(4), 821–829 (2012).
  Medline CASGoogle Scholar
• 111 Thomas L, Lai SY, Dong W et al. Sorafenib in metastatic thyroid cancer a systematic review. Oncologist 19(3), 251–258 (2014).
  Medline CASGoogle Scholar
• 112 Brose MS, Nutting CM, Sherman SI et al. Rationale and design of decision a double-blind, randomized, placebo-controlled Phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 11(1), 349 (2011).
  Medline CASGoogle Scholar
• 113 Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73‐4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129(1), 245–255 (2011).
  Medline CASGoogle Scholar
• 114 Grothey A, Cutsem EV, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303–312 (2013).
  Medline CASGoogle Scholar
• 115 Demetri GD, Reichardt P, Kang Y-K et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 295–302 (2013).
  Medline CASGoogle Scholar
• 116 George S, Wang Q, Heinrich MC et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib a multicenter Phase II trial. J. Clin. Oncol. 30(19), 2401–2407 (2012).
  Medline CASGoogle Scholar
• 117 Bruix J, Tak W-Y, Gasbarrini A et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, Phase II safety study. Eur. J. Cancer 49(16), 3412–3419 (2013).
  Medline CASGoogle Scholar
• 118 Ramurthy S, Subramanian S, Aikawa M et al. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J. Med. Chem. 51(22), 7049–7052 (2008).
  Medline CASGoogle Scholar
• 119 Garcia-Gomez A, Ocio EM, Pandiella A, San Miguel JF, Garayoa M. RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest. New Drugs 31(1), 200–205 (2013).
  Medline CASGoogle Scholar
• 120 Su Y, Vilgelm AE, Kelley MC et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res. 18(8), 2184–2198 (2012).
  Medline CASGoogle Scholar
• 121 Zambon A, Niculescu-Duvaz I, Niculescu-Duvaz D, Marais R, Springer CJ. Small molecule inhibitors of BRAF in clinical trials. Bioorg. Med. Chem. Lett. 22(2), 789–792 (2012).
  Medline CASGoogle Scholar
• 122 Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9(8), 550–562 (2009).
  Medline CASGoogle Scholar
• 123 Banerjee S, Mehta S, Haque I et al. VEGF-A165 induces human aortic smooth muscle cell migration by activating Neuropilin-1-VEGFR1-PI3K Axis. Biochemistry 47(11), 3345–3351 (2008).
  Medline CASGoogle Scholar
• 124 Ruan GX, Kazlauskas A. Axl is essential for VEGF‐A‐dependent activation of PI3K/Akt. EMBO J. 31(7), 1692–1703 (2012).
  Medline CASGoogle Scholar
• 125 Zhao YW, Jin L, Li ZM, Zhao CJ, Wei YQ, Yang HS. Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3‐kinase/Akt pathway during anti‐angiogenesis therapy. Cancer Sci. 102(8), 1469–1475 (2011).
  Medline CASGoogle Scholar
• 126 Apsel B, Blair JA, Gonzalez B et al. Targeted polypharmacology discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Bio. 4(11), 691–699 (2008).
  Medline CASGoogle Scholar
• 127 Brown A, Shi Q, Moore TW et al. Monocarbonyl curcumin analogues heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties. J. Med. Chem. 56(9), 3456–3466 (2013).
  Medline CASGoogle Scholar
• 128 Taby R, Issa JP. Cancer epigenetics. CA Cancer J. Clin. 60(6), 376–392 (2010).
  MedlineGoogle Scholar
• 129 Robey RW, Chakraborty AR, Basseville A et al. Histone deacetylase inhibitors emerging mechanisms of resistance. Mol. Pharm. 8(6), 2021–2031 (2011).
  Medline CASGoogle Scholar
• 130 Scroggins BT, Robzyk K, Wang D et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 25(1), 151–159 (2007).
  Medline CASGoogle Scholar
• 131 Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5(10), 761–772 (2005).
  Medline CASGoogle Scholar
• 132 Kaluza D, Kroll J, Gesierich S et al. Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin. EMBO J. 30(20), 4142–4156 (2011).
  Medline CASGoogle Scholar
• 133 Qian DZ, Wang X, Kachhap SK et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 64(18), 6626–6634 (2004).
  Medline CASGoogle Scholar
• 134 Qian DZ, Kato Y, Shabbeer S et al. Targeting tumor angiogenesis with histone deacetylase inhibitors the hydroxamic acid derivative LBH589. Clin. Cancer Res. 12(2), 634–642 (2006).
  Medline CASGoogle Scholar
• 135 Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 280(2), 145–153 (2009).
  Medline CASGoogle Scholar
• 136 Yu C, Friday BB, Lai J-P et al. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin. Cancer Res. 13(4), 1140–1148 (2007).
  Medline CASGoogle Scholar
• 137 Jane EP, Premkumar DR, Addo-Yobo SO, Pollack IF. Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. J. Pharmacol. Exp. Ther. 331(1), 327–337 (2009).
  Medline CASGoogle Scholar
• 138 Curis Inc.: US20080234332 (2008).
  Google Scholar
• 139 Curis Inc.: US20090076044 (2009).
  Google Scholar
• 140 Curis Inc.: US007928136 (2011).
  Google Scholar
• 141 Chipscreen Biosciences Ltd.: US20090298886 (2009).
  Google Scholar
• 142 Chipscreen Biosciences Ltd.: WO10139180 (2010).
  Google Scholar
• 143 Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347), 298–307 (2011).
  Medline CASGoogle Scholar
• 144 Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J. Clin. 60(4), 222–243 (2010).
  MedlineGoogle Scholar
• 145 Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 6(10), 569–579 (2009).
  Medline CASGoogle Scholar
• 146 Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res. 14(20), 6371–6375 (2008).
  Medline CASGoogle Scholar
• 147 Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res. 15(24), 7471–7478 (2009).
  Medline CASGoogle Scholar
• 148 Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J. Clin. Oncol. 30(32), 4026–4034 (2012).
  Medline CASGoogle Scholar
• 149 Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24–40 (2006).
  Medline CASGoogle Scholar
• 150 Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592–603 (2008).
  Medline CASGoogle Scholar
• 151 Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3), 232–239 (2009).
  Medline CASGoogle Scholar
• 152 Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220–231 (2009).
  Medline CASGoogle Scholar
• 153 Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8(4), 210–221 (2011).
  Medline CASGoogle Scholar
• 154 Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT. Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep. 3(2), 277–281 (2013).
  Medline CASGoogle Scholar
• 155 Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer 12(5), 323–334 (2012).
  Medline CASGoogle Scholar
• 156 Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17(3), 320–329 (2011).
  Medline CASGoogle Scholar
• 157 Paget S. The distribution of secondary growths in cancer of the breast. Lancet 133(3421), 571–573 (1889).
  Google Scholar
• 158 Mcmillin DW, Negri JM, Mitsiades CS. The role of tumour–stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12(3), 217–228 (2013).
  Medline CASGoogle Scholar
• 159 Azmi AS, Mohammad RM. Rectifying cancer drug discovery through network pharmacology. Future Med. Chem. 6(5), 529–539 (2014).
  CASGoogle Scholar
• 160 Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10(2), 130–137 (2010).
  Medline CASGoogle Scholar
• 161 Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 73(16), 4965–4977 (2013).
  Medline CASGoogle Scholar
• 162 Chung AS, Wu X, Zhuang G et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 19(9), 1114–1123 (2013).
  Medline CASGoogle Scholar
• 163 Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21(3), 283–296 (2012).
  Medline CASGoogle Scholar
• 164 Sessa C, Guibal A, Del Conte G, Rüegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat. Clin. Prac. Oncol. 5(7), 378–391 (2008).
  Medline CASGoogle Scholar
• 165 Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy – evolving view based on clinical trial results. Nat. Rev. Clin. Oncol. 9(5), 297–303 (2012).
  Medline CASGoogle Scholar
• 166 Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4(6), 423–436 (2004).
  Medline CASGoogle Scholar